CAS: 54048-10-1; Etonogestrel

该化合物是源自19个诺氏酮的合成蛋白质,主要用于激素避孕,因为其具有很强的先兆活动,具有较高的生物利用率和长期作用,适合长期的避孕应用,如子皮肤植入和阴道环. 蛋白质功能通过抑制排卵,厚厚的宫颈肌肉和改变内衬,确保了可靠的避孕措施. 其稳定的药理基因特征允许持续释放荷尔蒙,最大限度地减少血浆浓度的波动. 化合物主要在肝脏中代谢,通过尿和粪便排出. 其功效,可预测性和低系统性副作用使得其在荷尔蒙避孕配方中成为首选.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号187538-71-2 (8S,9S,10R,13S,... | CAS号54024-22-5 去氧孕烯 | CAS号160683-92-1 13-ethyl-gona-4... | CAS号54024-21-4 13-乙基-11-亚甲基-4-... | CAS号160683-91-0 3,3-ethylenedit... | CAS号160683-96-5 (8S,9S,10R,13S,...

合成工艺路线路线简述

  • 合成目标产物 Etonogestrel 主要起始原料 Desogestrel
  • (文献来源)合成步骤主要原料 Desogestrel
13β-Ethyl-17α-Hydroxy-11-Methylene-,Cyclic 1,2-Ethanediyldithioacetal-18,19-Dinorpregn-4-En-20-Yn-3-One置于水体系中,用 四氢呋喃,甲醇 作为反应溶剂,化学反应 2.5H,以98%的收率获得产物依托孕烯
参考文献: Combined Synthesis Route For Etonogestrel And Desogestrel[fr] Voie De Synthèse Combinée De L'étonogestrel Et Du Désogestrel
标题: Combined Synthesis Route For Etonogestrel And Desogestrel[fr] Voie De Synthèse Combinée De L'étonogestrel Et Du Désogestrel
摘要:本发明涉及一种合成路线,以及通用公式vi和vii的类固醇衍生物,用于合成去甲酮地诺酮和依诺地诺酮.

海关参考信息

专利信息


专利号:US-9422326-B2
优先权日:2012-09-04
标 题:Process for preparing 11-methylene-18-methyl-estr-4-en-3, 17-dione, useful as intermediate compound for the synthesis of molecules having pharmacological activity
发明人:LENNA ROBERTO; MARIANI EDOARDO; VANOSSI ANDREA
权利人:IND CHIMICA SRL
摘要:There is described a process for the industrial synthesis of 11-methylene-18-methyl-estr-4-en-3,17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel.

专利号:US-9464108-B2
优先权日:2012-03-15
标 题:Combined synthesis route for desogestrel and etonogestrel
发明人:OSTENDORF MARTIN
权利人:MSD OSS BV; MERCK SHARP & DOHME
摘要:The present invention relates to a synthesis route and to steroid derivatives of general formula VI and VII useful in the synthesis of desogestrel and etonogestrel.

专利号:WO-2004101594-A1
优先权日:2003-05-14
标题 :New mono-and bismethylene-steroid derivatives and process for their synthesis
发明人:TUBA ZOLTAN; DANCSI LAJOSNE; FRANCSICSNE CZINEGE ERZSEBET; FALKAY GYOERGY; ZUPKO ISTVAN; MARKI ARPAD; MOLNAR CSABA; CSOERGEI JANOS; DUKATNE ABROK VILMA; BALOGH GABOR; MAK MARIANNA
权利人:RICHTER GEDEON VEGYESZET; TUBA ZOLTAN; DANCSI LAJOSNE; FRANCSICSNE CZINEGE ERZSEBET; FALKAY GYOERGY; ZUPKO ISTVAN; MARKI ARPAD; MOLNAR CSABA; CSOERGEI JANOS; DUKATNE ABROK VILMA; BALOGH GABOR; MAK MARIANNA
摘要:The invention relates to new mono- and bismethylene-steroid derivatives of general formula (I) - wherein Z represents two hydrogen atoms or an oxo group; X and Y independently of each other represent either two hydrogen atoms of a CH2= group, with the restriction that at least one of them is CH2= group and if the meaning of Z is oxo group Y represents two hydrogen atoms, R represents a C1-C4 alkyl group, as well as the pharmaceutical compositions containing the above compounds as active ingredients, and the processes for the synthesis of active ingredients and pharmaceutical compositions. The invention also relates to the methods of treatments with these compounds, which means administering to a mammal to be treated with progestogen - including human - effective amount/amounts of the active ingredients of the present invention as such or as medicament. The mono- and bismethylene-steroid derivatives of the general formula (I) have progestogen effect. They can be used as active ingredients of contraceptive medicaments as such or in combination with an estrogen component. Furthermore, they can be used in the treatment of endometriosis and in the substitution therapy of estrogen as gestagen agent beside the estrogen component. The mono- and bismethylene-steroid derivatives of the general formula (I) of the present invention can be synthesized by reacting a compound of the general formula (II), - wherein the meaning of Z, X and Y is as described for the compounds of formula (I) - with an acid anhydride of the general formula (R-CO)2O or with an acid chloride of the general formula R-CO-Cl - wherein R represents a C1-C4 alkyl group - in the presence of a strong acid.

专利号:US-2013123523-A1
优先权日:2011-11-10
标 题:Methods for the preparation of etonogestrel and desogestrel
发明人:NICKISCH KLAUS; SANTHAMMA BINDU
权利人:NICKISCH KLAUS; SANTHAMMA BINDU
摘要:Described herein is a process for the synthesis of etonogestrel and desogestrel and intermediates used to form etonogestrel and desogestrel.

专利号:US-7667056-B2
优先权日:2002-08-02
标 题 :Process and new intermediates for the preparation of steroids with a progestogen activity
发明人:GRISENTI PARIDE; PECORA FABIO; VERZA ELISA; LEONI MASSIMO; BOSSI LAURA
权利人:POLI IND CHIMICA SPA
摘要:The present invention relates to a new process of synthesis and to some new intermediates for the preparation of steroids with progestogen activity, more particularly, for the preparation of Desogestrel of formula (I). Said process is characterized by the regioselective reduction of the compound of formula (II) to give the intermediate of formula (III).

专利号:US-2008234340-A1
优先权日:2007-03-09
标 题:Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile
发明人:MIRMEHRABI MAHMOUD; NIU YUPING; TADAYON ABDOLSAMAD; DESHMUKH SUBODH; KU MANNCHING SHERRY
权利人:WYETH CORP
摘要:A polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form II are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. n Further provided are methods for preparing polymorph Form I of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile from polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile.
杭州德立化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.dlchemical.com
企业联系电话:0571-28006267👤
📞杭州德立化工有限公司 ⚠️参考联系方式
联系人:朱经理
电话:0571-28006267

传真:0571-28006269
邮箱:exp@dlchemical.com
通信地址: 西湖区古墩路387号金桂大厦
邮编: 310012
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:西湖区古墩路387号金桂大厦
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
浙江仙琚制药股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.xjpharma.com
电话: 0576-87772810👤
📞浙江仙琚制药股份有限公司 ⚠️参考联系方式

销售电话:0576-87772810
邮箱:online@xjpharma.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
杭州荣大医药化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.rdpharm.com
企业联系电话:0571-88088387👤
📞杭州荣大医药化工有限公司 ⚠️参考联系方式
联系人:陈/赵
电话:0571-88088387
手机:18605818038
传真:0571-88088387-802
邮箱:sales@rdpharm.com
通信地址: 浙江省杭州市上城区丁桥置鼎时代中心4幢1012室
邮编: 310021
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省杭州市上城区丁桥置鼎时代中心4幢1012室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
北京上草生物科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.china-api.cn
企业联系电话:010-51288246👤
📞北京上草生物科技有限公司 ⚠️参考联系方式
联系人:杨先生
电话:010-51288246

传真:010-56495849
邮箱:300abc@sina.com
通信地址: 北京市通州区金桥科技产业基地景盛南四街17号联东U谷58号楼
邮编: 101102
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:北京市通州区金桥科技产业基地景盛南四街17号联东U谷58号楼
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Moray KV, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health. 2021 Jan 6;18(1):4. doi: 10.1186/s12978-020-01054-y.
2: Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018 Nov;110(6):1129-1136. doi: 10.1016/j.fertnstert.2018.07.003. 68(8):594. doi: 10.46747/cfp.6808594.
4: Clermidy H, Fabre D, Hugues JN, Alonso CG, Mitilian D, Mercier O, Brenot P, Charbonneau P, Fadel E. Management of Etonogestrel implant migration into the pulmonary artery. Contraception. 2022 Sep;113:62-67. doi: 10.1016/j.contraception.2022.03.017. Epub 2022 Mar 26. 24(22):11810-11819. doi: 10.26355/eurrev_202011_23838. 133(4):780-782. doi: 10.1097/AOG.0000000000003152. 193(31):E1218. doi: 10.1503/cmaj.202413.

合成参考文献


参考文献:10.1016/s0368-2315(05)82961-8
摘要:Jasaitis Y, Diguet A, Sergent F. [Is the etonogestrel contraceptive implant 100% sure Concerning the article << Ectopic pregnancy with etonogestrel contraceptive implant (Implanon) >> by M. Mansour, C. Louis-Sylvestre and B.-J. Paniel (J Gynecol Obstet Biol Reprod n degree 6-2005)]. J Gynecol Obstet Biol Reprod (Paris). 2005 Dec;34(8):819–20; author reply 820. doi: 10.1016/s0368-2315(05)82961-8.
参考文献:10.1016/j.contraception.2009.09.011
摘要:Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception. 2010 Mar;81(3):209–14. doi: 10.1016/j.contraception.2009.09.011.
参考文献:10.1016/j.contraception.2009.10.007
摘要:Barreiros FA, Guazzelli CA, Barbosa R, de Assis F, de Araújo FF. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception. 2010 Mar;81(3):223–5. doi: 10.1016/j.contraception.2009.10.007.
参考文献:10.1016/j.contraception.2010.11.002
摘要:Barreiros FA, Guazzelli CA, Barbosa R, Torloni MR, Barbieri M, Araujo FF. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. Contraception. 2011 Aug;84(2):155–9. doi: 10.1016/j.contraception.2010.11.002.
参考文献:10.1016/j.gyobfe.2005.10.016
摘要:Bensouda-Grimaldi L, Jonville-Béra AP, Beau-Salinas F, Llabres S, Autret-Leca E; le réseau des centres régionaux de pharmacovigilance. [Insertion problems, removal problems, and contraception failures with Implanon]. Gynecol Obstet Fertil. 2005 Dec;33(12):986–90. doi: 10.1016/j.gyobfe.2005.10.016.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知